Caris Target Now has been updated to offer both on- and off-Compendium therapeutic associations for all solid tumours, across a wide range of evidence.
The product identifies the genomic information specific to a patient’s tumour based on the presence of relevant biomarkers.
The technology provides focused biomarker profiles designed for earlier-stage cancer patients and also offers the advantages of known "on-Compendium-only" drug associations, faster turnaround time,up to 30 reported biomarkers per patient (depending on tumor type),the capability to derive meaningful results from smaller tissue samples and for the first time clinical trials connector, a service that enables biomarker-specific clinical trial matching.
Caris Life Sciences CEO David D. Halbert said, "With these enhancements, we believe we can prolong the lives of patients and improve outcomes, while also lowering costs to the healthcare system."
Caris Life Sciences senior medical director Sandeep Reddy said, "Caris Target Now Select is an evidence-based molecular profiling service that can help both earlier-stage and later-stage cancer patients, as it employs the most relevant biomarkers and technologies to help decode a patient’s tumor."